Skip to Content

Tag: Zepbound


News

FDA approves GLP-1 for OSA 

December 23, 2024HME News Staff

WASHINGTON – The U.S. Food and Drug Administration announced Dec. 20 that it has approved Zepbound (tirzepatide) for the treatment of moderate to severe sleep apnea in adults with obesity to be used in combination with a reduced-calorie diet and increased physical activity.  “Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical...

Food & Drug Administration (FDA), Sleep Apnea, weight loss drugs, Zepbound


Read Full Articlered right arrow icon